A Management Of The Exposed Site

medical resources He/she may have access to the medical record and know the HIV status of the source patient, as well as information about drug resistance, Therefore in case the exposed worker is part of the healthcare team. If available, information about drug regimens, and, resistance information, gonna be made available to the exposed employee’s provider to determine top regimen for the employee. Expert consultation could be sought. For individuals exposed to HCVinfected source patients, regular followup with HCV RNA testing is recommended in addition to HCV antibody testing, as HCV RNA testing can identify acute infection within 2 exposure weeks, whereas accuracy of the antibody test can be delayed up to a couple of months after acute infection.

Seroconversion with the ELISA antibody test occurs in 50percentage of patients within 9 exposure weeks, in 80 of patients within 15 exposure weeks, and in at least 97percent of patients within 6 months of exposure dot 36 The ELISA test is highly sensitive but relatively nonspecific, resulting in a low positive predictive value in low prevalence populations.

The risk of transmission of hepatitis B virus and hepatitis C virus from an occupational exposure is significantly greater than the risk of HIV transmission.

medical resourcesThe risk of HCV infection following a needlestick is 8, whereas the risk of HBV infection ranges from 1 to 30 relying upon the presence of hepatitis e antigen. Initiation of PEP in exposed workers who are breastfeeding requires careful discussion, breastfeeding could be avoided for 3 months after the exposure to prevent HIV transmission and potential drug toxicities dot 34 Clinicians should discuss the risks and benefits with the exposed worker, Both HIV and antiretroviral drugs should be found in breast milk.

Followup testing is necessary to confirm the source patient’s status, Therefore in case the source patient is tested with a EIA/ELISA and found to be positive. HCV RNA should be used as the confirmatory test. While recommending a potent but very well tolerated ‘firstline’ triple therapy for all significant exposures, the guidelines of this committee stress simplicity and tolerability in the approach to PEP. Immunoglobulin and antiviral agents are not recommended for HCV PEP. Currently, no effective prophylaxis for HCV is identified. You should take this seriously. If an individual becomes acutely infected with HCV and is diagnosed at that time, immediate referral to a specialist experienced in the treatment of HCV is strongly recommended.

By the way, the employer must ensure that any employee who sustains an occupational exposure has access to ‘post exposure’ services.

medical resources

Services must be available 24 hours per day, 7 days per week. Whenever testing for the source individual’s known HBV, HCV, or HIV status does not need to be repeated, when the source patient is already known to be infected with HBV, or HIV. Placebocontrolled clinical trials of PEP in humans have not been conducted and are not feasible to design, the NYSDOH AI guidelines are depending on existing published studies, ‘bestpractice’ evidence, and the considered opinion of the expert clinicians in the field of adult HIV medicine who comprise the Medical Care Criteria Committee, since randomized. I’m sure that the purpose of these guidelines is to provide recommendations for prescribing HIV postexposure prophylaxis following occupational exposure. New York State Department of Health AIDS Institute’s Medical Care Criteria Committee has reviewed available literature addressing the biologic efficacy, effectiveness, and implementation of PEP, as well as current standards for the use of antiretroviral therapy in established HIV infection, with the intention to develop these guidelines. Factors that may increase the risk of sexual transmission include sex with multiple partners, history of STIs, including HIV, or any other practice that might disrupt mucous membranes.

PESH and OSHA’s Bloodborne Pathogen Standards indicate that the covered employer is responsible for all costs associated with an exposure incident. Employer may not require any out of pocket expenditures on behalf of the employee, similar to requiring the employee to utilize workers’ compensation if prepayment is required or compelling an employee to use hospital insurance to cover these expenses the employer pays all premiums and deductible costs associated with the employees’ medical insurance. Organizations that employ health professionals and akin persons who are at risk for occupational exposure to blood, body fluids, and similar potentially infectious materials are generally required to establish policies and procedures that guide the management of such exposures. Employers must conform to the OSHA Bloodborne Pathogen Standard, that are applicable to NYC public employers under the New York City Public Employee Safety and Health Act and regulations. You should take it into account. OSHA and PESH standards with regard to occupational exposure to bloodborne pathogens are identical. Post exposure policies should define for purposes of providing care. Staff who are clearly employed by an organization, consideration must be given to whether other individuals gonna be covered by the institution’s policy.

However, clinicians going to be aware that these agents should’ve been prescribed in exposed workers who are pregnant, The agents listed in Table 7 are all ‘nonpreferred’ agents for use in PEP regimens and are not going to be used.

The medications listed below include antiretroviral agents recommended for PEP as well as alternative antiretroviral drugs that might be used in the setting of potential HIV resistance, toxicity risks, or constraints on the availability of particular agents.

For information on all antiretroviral medications, see More information about these antiretroviral agents, including dosage and dose adjustment, potential adverse events and drug interactions, and FDA pregnancy categories, can be found in Antiretroviral Therapy, Appendix FDA Approved HIV Medications and FDA Pregnancy Categories.

Comments Are Closed!!!